SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Fly-E Group, Inc. is an electric vehicle company, which engages in designing, installing, and selling smart electric motorcycles, electric bikes, electric scooters, and related accessories under the brand Fly E-Bike. Its products include electric-scooter, e-bikes, parts, and accessories. The company was founded by Zhou Ou in 2018 and is headquartered in Flushing, NY.

Fly-E Group Inc.

Fly-E Group Inc

FLYE is trending due to a massive intraday price surge, with community members discussing potential short squeeze opportunities given the high short interest and low float. Some traders caution about the stock's volatility and past history, while others point to potential for further gains. Overall, the stock's unusual price action is fueling speculative interest.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

TLRY is trending due to a 1-for-10 reverse stock split, leading to discussions about its impact on share value and potential for institutional investment. The community is debating the CEO's motives behind the split and its timing, with some expressing concern about potential dilution and others anticipating a future surge based on cannabis rescheduling news from the Trump administration. Investor sentiment is highly volatile, reflecting uncertainty about the company's direction following the split.

Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded by David Campbell in June 2017 and is headquartered in San Diego, CA.

Janux Therapeutics Inc

Janux Therapeutics ($JANX) is trending due to mixed reactions to recent Phase 1 data for its JANX007 prostate cancer treatment, with the stock plummeting in after-hours trading despite analysts' initial positive assessments. The community is debating the efficacy compared to existing treatments and the potential impact of patient selection on the results, while some view the selloff as an overreaction and a buying opportunity, anticipating future data readouts and a potential buyout.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology is trending after reporting strong earnings and revenue growth, driven by demand for its high-speed connectivity solutions in AI infrastructure. The community is discussing the company's potential for further gains, especially given its strategic partnerships with hyperscalers. However, some are wary of the stock's high valuation and potential for a pullback.

Monad is a high-performance Layer 1 blockchain that processes 10,000 transactions per second with near-zero fees. The platform delivers high performance without compromising on security or decentralization, creating the infrastructure needed for complex applications that require high-frequency activity.  One of Monad’s key innovations lies in how it handles transaction processing. Instead of processing transactions one at a time like traditional blockchains, Monad processes multiple transactions simultaneously through parallel execution.   The system separates the agreement process from the execution process, allowing validators to first agree on which transactions to include and in what order, then having more time to execute those transactions without slowing down consensus. This approach, combined with a custom-built database called MonadDB, dramatically increases throughput while maintaining accuracy.  Monad also offers complete EVM compatibility, where applications built for Ethereum work on Monad without any code modifications, and users can connect with familiar wallets like MetaMask just as they would on Ethereum. Developers can immediately tap into Ethereum's established ecosystem of tools, libraries, and applications while benefitting from Monad’s performance improvements. The platform also runs on consumer-grade hardware rather than expensive specialized equipment, making it accessible for more people to participate in securing the network.  Monad has raised approximately 244 million dollars in total funding across multiple rounds. The company secured 19 million dollars in a seed round in February 2023 led by Dragonfly Capital, followed by a 225 million dollar Series A round in April 2024 led by Paradigm at a 3 billion dollar valuation. Other notable investors include Electric Capital, Greenoaks, Coinbase Ventures, and prominent angel investors such as Naval Ravikant.

Monad

Monad (MON) is trending as the community discusses its potential and future price targets, with some members expressing strong bullish sentiment and advocating for long-term holding. Recent volatility and a pullback from initial highs have sparked debates about its classification as a potential "scam" versus a promising layer-1 project, while others highlight the importance of considering tokenomics and upcoming unlocks.

ProShares Trust - ProShares UltraShort Silver -2x Shares

ProShares UltraShort Silver

$ZSL is trending as traders discuss potential short-term pullbacks in silver, looking for opportunities to profit from a reversal. Community members are actively debating entry points, technical indicators, and potential options strategies, with some expressing skepticism towards those heavily promoting silver. Concerns about manipulation and the overall direction of the silver market are also prevalent.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending amid anticipation of HOPE-3 trial data release, with community discussions focused on the potential for positive results and a short squeeze. Concerns about a negative report from Martin Shkreli are countered by optimism surrounding the drug's efficacy and ongoing developments with the StealthX exosome platform. Traders are closely watching for news, potential leaks, and the possibility of a significant price movement.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in November 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDB is trending following positive earnings results, with discussions centering on strong cloud growth and operating leverage. Upgrades from analysts, including Piper Sandler's Overweight rating and target price adjustment, are fueling optimism. The community is actively discussing the potential for further gains and comparing MDB's performance to competitors like Oracle.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is trending as traders discuss its impressive year-to-date growth and upcoming earnings, but some express concerns about valuation and increasing competition. A recent Cyber Monday outage negatively impacted the stock, while some analysts maintain a bullish outlook. Community members are actively debating the sustainability of its business model and the potential impact of AI.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTech is trending following news of a collaboration with Bristol Myers Squibb to co-develop a cancer drug, with community members discussing the financial implications of the deal and the potential for future growth in the oncology space.  However, some are wary, pointing to a recent history of insider selling, while others discuss potential links between mRNA vaccines and adverse health outcomes.  Overall sentiment seems mixed with excitement around new developments offset by skepticism related to the company's past.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FluoroPharma Medical, Inc. engages in the discovery, development, and commercialization of proprietary medical diagnostic imaging products. The company was founded on January 25, 2007 and is headquartered in Carson City, NV.

FluoroPharma Medical Inc

$CRWD

$CRM

$SNOW

$MDB

Which earnings report are you most looking forward to this week? 
 
Drop a comment for others.

Current Price	$0.0002
Prev Close	N/A
Open	$0.0002
Dividend Yield	N/A
50-Day Moving Average	$0.00
Beta	0.00
Avg. Volume	28,301.32
PE Ratio	N/A

52-Week High	$0.0002
52-Week Low	$0.00
Market Capitalization	$34.00
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

FPMI
Fluoropharma Medical Inc

Feed

News

Sentiment

Fundamentals

Info

Latest FPMI News

FPMIFluoropharma Medical Inc